PACIRA BIOSCIENCES, INC.

NASDAQ: PCRX (Pacira BioSciences, Inc.)

最近更新时间: 22 May, 4:23PM

26.07

-0.07 (-0.27%)

前收盘价格 26.14
收盘价格 26.11
成交量 605,456
平均成交量 (3个月) 974,241
市值 1,207,163,520
预期市盈率 (P/E Forward) 9.67
价格/销量 (P/S) 1.74
股市价格/股市净资产 (P/B) 1.57
52周波幅
11.16 (-57%) — 31.64 (21%)
利润日期 28 Jul 2025 - 1 Aug 2025
营业毛利率 -14.20%
营业利益率 (TTM) 15.77%
稀释每股收益 (EPS TTM) -2.15
季度收入增长率 (YOY) 3.30%
季度盈利增长率 (YOY) -35.50%
总债务/股东权益 (D/E MRQ) 82.08%
流动比率 (MRQ) 2.40
营业现金流 (OCF TTM) 189.39 M
杠杆自由现金流 (LFCF TTM) 163.38 M
资产报酬率 (ROA TTM) 3.90%
股东权益报酬率 (ROE TTM) -12.08%

市场趋势

短期 中期
行业 Drug Manufacturers - Specialty & Generic (US) 看跌 混合的
Drug Manufacturers - Specialty & Generic (全球的) 看跌 混合的
股票 Pacira BioSciences, Inc. 看涨 看涨

AIStockmoo 评分

0.1
分析师共识 3.0
内部交易活动 NA
价格波动 -4.5
技术平均移动指标 0.0
技术振荡指标 2.0
平均 0.13

相关股票

股票 市值 DY P/E(TTM) P/B
PCRX 1 B - - 1.57
RGC 8 B - - 985.78
BGM 2 B - - 37.55
INDV 2 B - - 145.25
ANIP 1 B - - 3.90
COLL 978 M - 24.95 4.17

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

部门 Healthcare
行业 Drug Manufacturers - Specialty & Generic
投资方式 Small Value
内部持股比例 1.77%
机构持股比例 107.04%
52周波幅
11.16 (-57%) — 31.64 (21%)
目标价格波幅
30.00 (15%) — 65.00 (149%)
65.00 (HC Wainwright & Co., 149.33%) 购买
47.50 (82.20%)
30.00 (Needham, 15.08%) 购买
平均值 47.50 (82.20%)
总计 2 购买
平均价格@调整类型 25.70
公司 日期 目标价格 调整类型 价格@调整类型
Needham 09 May 2025 30.00 (15.07%) 购买 25.12
08 Apr 2025 32.00 (22.75%) 购买 26.27
HC Wainwright & Co. 08 Apr 2025 65.00 (149.33%) 购买 26.27

该时间范围内无数据。

日期 类型 细节
11 Jun 2025 公告 Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
05 Jun 2025 公告 Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 May 2025 公告 Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
14 May 2025 公告 Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
08 May 2025 公告 Pacira BioSciences Reports First Quarter 2025 Financial Results
06 May 2025 公告 Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis
02 May 2025 公告 Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis
29 Apr 2025 公告 Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025
28 Apr 2025 公告 Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee
22 Apr 2025 公告 Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee
21 Apr 2025 公告 DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
17 Apr 2025 公告 Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
11 Apr 2025 公告 Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Apr 2025 公告 Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
03 Apr 2025 公告 Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
01 Apr 2025 公告 Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
14 Mar 2025 公告 Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
14 Mar 2025 公告 DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票